Palm Beach Compounding (DNA Pharmacy Services, Inc.), Jupiter, FL

Is Palm Beach Compounding (DNA Pharmacy Services, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Ceased sterile compounding”.

Does Palm Beach Compounding (DNA Pharmacy Services, Inc.) hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH20850 for DNA PHARMACY SERVICES, INC (dba PALM BEACH COMPOUNDING SERVICES), JUPITER, status Closed and PH27828 for DNA PHARMACY SERVICES INC, JUPITER, status Error.

Has Palm Beach Compounding (DNA Pharmacy Services, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Mar 5, 2019) for Palm Beach Compounding (DNA Pharmacy Services, Inc.). State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 4 actions: “Restriction Satisfied” dated Nov 3, 2014, case 201309736 on license PH20850, “Restriction Satisfied” dated Nov 3, 2014, case 201218237 on license PH20850 and “Administrative Complaint Filed” dated Jun 20, 2014, case 201309736 on license PH20850, and 1 more listed below.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
DNA Pharmacy Services, Inc.; Palm Beach Compounding
Location
Jupiter, FL
Type as FDA labels it
503A
FDA’s note
Ceased sterile compounding
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Mar 5, 2019
FDA Data Dashboard inspections
2 inspections: 2 VAI; 2 published Form 483s
Form 483 text on this page
2 Form 483s, 4 observations
State board records
License found: PH20850, Closed; PH27828, Error

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as DNA Pharmacy Services, Inc. (dba Palm Beach Compounding), a 503A facility, with 1 dated action.

Document
Mar 5, 2019FMD-145 letterFMD 145 Letter Issued 03/05/2019Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists DNA Pharmacy Services Inc, Jupiter, FL (FEI number 3004962739), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 23, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30049627391021439
Aug 13, 2014Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI)3004962739892682

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 4 numbered observations in all, across 2 inspections ending Jul 17, 2015 to May 23, 2017. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 15, 2017 to May 23, 2017: 1 observation

Firm on the cover
DNA Pharmacy Services dba Palm Beach Compounding, 2151 South Alternate Drive A1A, Suite 1500, Jupiter, Florida 33477
FEI number
3004962739
Establishment type on the cover
Producer of non-sterile drugs
FDA district office on the cover
Not read
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

:

Hazardous drugs were produced without providing adequate cleaning of utensils and work surfaces to prevent cross-contamination.

Specifically, I observed the (b) (4) used to (b) (4) , was stored in alcohol between use rather than cleaned (detergent and sanitized). You do not have documentation to support the cleaning practices and maintenance of the (b) (4) .

Also, your operations include the preparation of non-sterile drug products that contain hormones, such as testosterone and progesterone, using reusable equipment that was cleaned with a (b) (4) with (b) (4) detergent or (b) (4) with (b) (4) (b) (4)soap. Working surfaces are wiped down using (b) (4) You do not have documentation to show that these methods are effective in removing and neutralizing these drug residues. Examples of these preparations include:

A. Testosterone (b) (4), lot (b) (4) , drug substance was used to prepare "Test/DHEA/Prog/ Anastrozole" troche butterscotch 110/10/5/0.5mg, lot 04/21/2017:0308.

Add Continuation Page

B. ...

Read the full 483 (PDF on fda.gov)

Inspection dated Jul 17, 2015 by FDA (dates on the form not read): 3 observations

Firm on the cover
DNA Pharmacy Services Inc dba Palm Beach, 2151 SOuth Alternate A1A S Uite 150, J upiter FL 334 77
FEI number
3004962739
Establishment type on the cover
Prod ucer of n on-s terile drugs
FDA district office on the cover
555 W 8/11/2014 - 08 / 13/2014
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, there is no data to juStify the beyond use date of more than 9 months for Testosterone Cypionate Injection 220mg/mL Lot 03/02/2014:1106 that you produced on 03/02/2014 and currently distribute with a BUD of 12/27/2014. The stability data you generated for this product only supports a BUD of 3 months.

Observation 2

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, Testosterone Cypionate Injection.220mg/mL Lot 03/02/2014:1106 produced on 03/02/2014 is currently d istributed with a BUD of 12/27/2014 (9 months) even though there is no current sterility and endotoxin testing data to d emonstrate that this lot is safe, effective, and stable for nine months.

Observation 3

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, during the walkthrough of the laboratory, I observed white residue and scratches inside the REDACTION (b)(4) (a componenet used as part of the high-torque REDACTION (b)(4) blender) used to blend inactive pharmaceutical ingredients) before encapsulation. Additionally, materials blended using the REDACTION (b)(4) blender are not tested to ensure that the high-torque and friction do not negatively affect the finish product quality attnbutes.

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH20850PharmacyDNA PHARMACY SERVICES, INC (dba PALM BEACH COMPOUNDING SERVICES)JUPITERClosed
PH27828PharmacyDNA PHARMACY SERVICES INCJUPITERError

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.